Purple Biotech (PPBT) vs Alaunos Therapeutics (TCRT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Alaunos Therapeutics is the larger company by market cap ($2.3 million vs $2.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PPBT | TCRT |
|---|---|---|
| Share price | $1.39 | $0.8021 |
| Market cap | $2.26M | $2.35M |
| 1-day change | -3.47% | +2.70% |
| EPS (TTM) | $-47.64 | $-1.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.10 | $4.50 |
| 52-week low | $1.16 | $0.72 |
| Distance from 52-week high | -90.14% | -82.18% |
| Analyst consensus | none | — |
| Avg. price target upside | +1123.02% | — |
| Average volume | 1.28M | 797.20K |
| Shares outstanding | 1.63M | 2.93M |
| Employees | 10 | 1 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Purple Biotech
PPBT stock →Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and CAPTN-3 - IM1240 and IM1305, multi-valent antibody designed to activate anti-tumoral immune response against TAA positive tumors, which is in preclinical stage.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
About Alaunos Therapeutics
TCRT stock →Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
PPBT vs TCRT FAQ
Which is bigger, Purple Biotech or Alaunos Therapeutics?
Alaunos Therapeutics (TCRT) is larger, with a market capitalization of $2.35M compared with $2.26M for Purple Biotech (PPBT).
Are Purple Biotech and Alaunos Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.